Literature DB >> 18434900

Effect of insulin therapy on coagulation and fibrinolysis in medical intensive care patients.

Lies Langouche1, Wouter Meersseman, Sarah Vander Perre, Ilse Milants, Pieter J Wouters, Greet Hermans, Jakob Gjedsted, Troels K Hansen, Jozef Arnout, Alexander Wilmer, Miet Schetz, Greet Van den Berghe.   

Abstract

OBJECTIVE: Most intensive care deaths beyond the first few days of critical illness are attributable to nonresolving organ failure, either due to or coinciding with sepsis. One of the mechanisms that is thought to contribute to the pathogenesis of organ failure is microvascular thrombosis. Recently, we reported significant improved survival and prevention of organ failure with the use of intensive insulin therapy to maintain normoglycemia for at least several days. We hypothesize that intensive insulin therapy also prevents severe coagulation abnormalities thereby contributing to less organ failure and better survival.
DESIGN: This was a preplanned subanalysis of a large randomized controlled study, conducted at a university hospital medical intensive care unit. The intervention was strict blood glucose control to normoglycemia with insulin.
RESULTS: Mortality of intensive insulin-treated patients was lower than that of conventionally treated patients for all classes of upon-admission disseminated intravascular coagulation (DIC) scores, except for those patients with overt DIC scores of 6 or higher (for DIC < 5, p = 0.003; for DIC > or = 5, p = 0.4). There was no effect of insulin therapy on any of the fibrinolytic, coagulation, or inflammatory parameters tested.
CONCLUSIONS: This negative observation does not support a key role for these systems in explaining the clinical benefit of intensive insulin therapy, although a short-lived effect within 5 days of treatment cannot be excluded.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18434900     DOI: 10.1097/CCM.0b013e31816f7bae

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  6 in total

1.  Organ failure and tight glycemic control in the SPRINT study.

Authors:  J Geoffrey Chase; Christopher G Pretty; Leesa Pfeifer; Geoffrey M Shaw; Jean-Charles Preiser; Aaron J Le Compte; Jessica Lin; Darren Hewett; Katherine T Moorhead; Thomas Desaive
Journal:  Crit Care       Date:  2010-08-12       Impact factor: 9.097

2.  Blood glucose as a marker of venous thromboembolism in critically ill children.

Authors:  J A Tala; C T Silva; S Pemira; E Vidal; E V S Faustino
Journal:  J Thromb Haemost       Date:  2014-06       Impact factor: 5.824

3.  Critical illness induces alternative activation of M2 macrophages in adipose tissue.

Authors:  Lies Langouche; Mirna B Marques; Catherine Ingels; Jan Gunst; Sarah Derde; Sarah Vander Perre; André D'Hoore; Greet Van den Berghe
Journal:  Crit Care       Date:  2011-10-21       Impact factor: 9.097

4.  Adiponectin, retinol-binding protein 4, and leptin in protracted critical illness of pulmonary origin.

Authors:  Lies Langouche; Sarah Vander Perre; Jan Frystyk; Allan Flyvbjerg; Troels Krarup Hansen; Greet Van den Berghe
Journal:  Crit Care       Date:  2009-07-09       Impact factor: 9.097

Review 5.  Venous thromboembolism has the same risk factors as atherosclerosis: A PRISMA-compliant systemic review and meta-analysis.

Authors:  Yuhong Mi; Shufeng Yan; Yanhui Lu; Ying Liang; Chunsheng Li
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

Review 6.  Therapeutic effect of intensive glycemic control therapy in patients with traumatic brain injury: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Chunran Zhu; Jinjing Chen; Junchen Pan; Zhichao Qiu; Tao Xu
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.